Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography
2003; Elsevier BV; Volume: 124; Issue: 7 Linguagem: Inglês
10.1016/s0016-5085(03)00384-6
ISSN1528-0012
AutoresBill Murray, Ross Carter, C W Imrie, Susan Evans, C.B.Ó. Súilleabháin,
Tópico(s)Pancreatic and Hepatic Oncology Research
ResumoBackground & Aims:Acute pancreatitis following endoscopic retrograde cholangiopancreatography presents a unique opportunity for prophylaxis and early modification of the disease process because the initial triggering event is temporally well defined and takes place in the hospital. We report a prospective, single-center, randomized, double-blind controlled trial to determine if rectal diclofenac reduces the incidence of pancreatitis following cholangiopancreatography.Methods:Entry to the trial was restricted to patients who underwent endoscopic retrograde pancreatography or had manometrically verified sphincter of Oddi hypertension. Immediately after endoscopy, patients were given a suppository containing either 100 mg diclofenac or placebo. Estimation of serum amylase levels and clinical evaluation were performed in all patients.Results:A total of 220 patients entered the trial, and 110 received rectal diclofenac. Twenty-four patients developed pancreatitis (11%), of whom 7 received rectal diclofenac and 17 received placebo (P < 0.05).Conclusions:This trial shows that rectal diclofenac given immediately after endoscopic retrograde cholangiopancreatography can reduce the incidence of acute pancreatitis.
Referência(s)